SERA — Sera Prognostics, Inc.

Summary of Sera Prognostics Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $14,000 for Q1 2026, down from $38,000 in Q1 2025, reflecting the ongoing transition in commercialization strategy.
• Operating Expenses: $9.4 million, slightly up from $9.3 million in the previous year, attributed to continued investments in advocacy and regulatory preparation.
• Net Loss: $8.4 million, compared to a net loss of $8.2 million in Q1 2025.
• Cash Position: $86.8 million in cash and equivalents, sufficient to fund operations through 2029 due to a strategic shift in spending towards commercialization.

2. Strategic Updates and Business Highlights

• Focus on building awareness and access for the PreTRM test, particularly following the PRIME study results.
• Launched a third partnership program aimed at reaching over 350 providers across three states, enhancing clinical footprint and risk identification for preterm births.
• Engaged with 13 payers across 15 states to deepen relationships and facilitate reimbursement strategies.
• Continued advocacy efforts, including a letter-writing campaign to encourage Medicaid coverage for the PreTRM test.
• Progress towards commercialization in Europe, with plans for CE Marking submission mid-year.

3. Forward Guidance and Outlook

• Revenue in 2026 expected to remain modest and uneven as the company pushes for reimbursement and awareness.
• Anticipation of increased adoption and revenue pull-through later in 2026 and into 2027.
• The company is on track to publish several PRIME sub-analyses throughout 2026, which are expected to strengthen the clinical and economic foundation for PreTRM adoption.

4. Bad News, Challenges, or Points of Concern

• Revenue decline indicates challenges in achieving immediate commercial traction despite strategic initiatives.
• The modest revenue reflects the timing of the commercialization strategy and the need for continued advocacy and awareness-building efforts.
• The transition to a more commercial focus may lead to reduced R&D capacity, which could impact future product development and innovation.
• Potential delays in Medicaid coverage decisions for the PreTRM test could hinder broader adoption.

5. Notable Q&A Insights

• The company plans to launch one partner program per quarter, emphasizing the importance of thorough integration with providers and payers.
• Metrics related to sales rep productivity are being monitored internally, with plans to report them once steady progress is observed.
• The timeline for Medicaid coverage decisions is estimated to be around two years, with the possibility of delays depending on data collection and analysis complexities.
• The shift in resources from R&D to commercial efforts was driven by reduced internal demand and external interest in collaborative R&D partnerships.

Overall, Sera Prognostics is focusing on building a solid foundation for the PreTRM test's adoption while navigating the challenges of commercialization and reimbursement in a competitive healthcare landscape.